BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/21/2019 9:31:55 AM | Browse: 204 | Download: 79
Publication Name World Journal of Gastroenterology
Manuscript ID 45008
Country of Manuscript Source Japan
Received
2018-12-07 06:01
Peer-Review Started
2018-12-08 14:19
To Make the First Decision
2018-12-29 00:54
Return for Revision
2018-12-29 04:00
Revised
2019-01-10 00:16
Second Decision
2019-01-14 09:17
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2019-01-15 01:35
Articles in Press
2019-01-15 01:35
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2019-02-20 10:24
Publish the Manuscript Online
2019-02-21 09:31
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Specialty Gastroenterology and Hepatology
Manuscript Type Minireviews
Article Title Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond
Manuscript Source Unsolicited Manuscript
All Author List Masatoshi Kudo
ORCID
Author(s) ORCID Number
Masatoshi Kudo http://orcid.org/0000-0002-4102-3474
Funding Agency and Grant Number
Corresponding author Masatoshi Kudo, MD, PhD, Director, Full Professor, Professor and Chairman, Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, 377-2, Ohno-Higashi, Osaka 589-8511, Japan. m-kudo@med.kindai.ac.jp
Keywords Hepatocellular carcinoma; Molecular targeted agent; Immune checkpoint inhibitor; Sorafenib; Lenvatinib
Core Tip Systemic therapy for hepatocellular carcinoma (HCC) has markedly advanced since sorafenib was approved in 2007. Since then, there was no active drug for 10 years that prolong overall survival, however, in 2017 and 2018, clinical trials of 4 more molecular targeted agents including lenvatinib as first line agent, regorafenib, cabozantinib and ramucirumab as second line agent have shown their survival benefit. In addition, immune check point inhibitors, nivolumab and pembrolizumab, were approved by Food and Drug Administration. Combination cancer immunotherapy, that combines immune checkpoint inhibitors and molecular targeted agents show great promise in the treatment of HCC.
Publish Date 2019-02-21 09:31
Citation Kudo M. Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond. World J Gastroenterol 2019; 25(7): 789-807
Url https://www.wjgnet.com/1007-9327/full/v25/i7/789.htm
DOI https://dx.doi.org/10.3748/wjg.v25.i7.789
Full Article (PDF) WJG-25-789.pdf
Full Article (Word) WJG-25-789.docx
Manuscript File 45008-Review.docx
Answering Reviewers 45008-Answering reviewers.pdf
Audio Core Tip 45008-Audio core tip.mp3
Conflict-of-Interest Disclosure Form 45008-Conflict-of-interest statement.pdf
Copyright License Agreement 45008-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate 45008-Language certificate.pdf
Peer-review Report 45008-Peer-review(s).pdf
Scientific Misconduct Check 45008-Scientific misconduct check.pdf
Scientific Editor Work List 45008-Scientific editor work list.pdf